DNA Methylation in Serum and Tumors of Cervical Cancer Patients

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 565-571

  Widschwendter, Andreas ^a   Müller, Hannes M ^a   Fiegl, Heidi ^a   Ivarsson, Lennart ^a   Wiedemair, Annemarie ^a   Müller Holzner, Elisabeth ^a   Goebel, Georg ^b   Marth, Christian ^a   Widschwendter, Martin ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD ANALYSIS; CALCA GENE; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FLUORESCENCE ANALYSIS; GENE; HIGH RISK PATIENT; HTERT GENE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOD1 GENE; PGR GENE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER HYPERMETHYLATION; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; SEROLOGY; TECHNIQUE; TIMP3 GENE; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; CALCITONIN; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; PROMOTER REGIONS (GENETICS); PROTEIN PRECURSORS; RECEPTORS, PROGESTERONE; TELOMERASE; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 0842290007     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0825-03     Document Type: Article

References (30)

1. Pisani, P., Parkin, D. M., Bray, F., and Ferlay, J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83: 18-29, 1999.
2. Graflund, M., Sorbe, B., Hussein, A., Bryne, M., and Karlsson, M. The prognostic value of histopathologic grading parameters and microvessel density in patients with early squamous cell carcinoma of the uterine cervix. Int. J. Gynecol. Cancer, 12: 32-41, 2002.
3. Takeda, N., Sakuragi, N., Takeda, M., Okamoto, K., Kuwabara, M., Negishi, H., Oikawa, M., Yamamoto, R., Yamada, H., and Fujimoto, S. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet. Gynecol. Scand., 81: 1144-1151, 2002.
4. Jones, P. A. DNA methylation errors and cancer. Cancer Res., 56: 2463-2467, 1996.
5. Jones, P. A., and Laird, P. W. Cancer epigenetics comes of age. Nat. Genet., 21: 163-167, 1999.
6. Dong, S. M., Kim, H. S., Rha, S. H., and Sidransky, D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res., 7: 1982-1986, 2001.
7. Virmani, A. K., Muller, C., Rathi, A., Zoechbauer-Mueller, S., Mathis, M., and Gazdar, A. F. Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res., 7: 584-589, 2001.
8. Anker, P., Mulcahy, H., Chen, X. Q., and Stroun, M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev., 18: 65-73, 1999.
9. Leon, S. A., Shapiro, B., Sklaroff, D. M., and Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res., 37: 646-650, 1977.
10. Ziegler, A., Zangemeister-Wittke, U., and Stahel, R. A. Circulating DNA: a new diagnostic gold mine? Cancer Treat. Rev., 28: 255-271, 2002.
11. Muller, H. M., and Widschwendter, M. Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev. Mol. Diagn., 3: 443-458, 2003.
12. Widschwendter, A., Blassnig, A., Wiedemair, A., Muller-Holzner, E., Muller, H. M., and Marth, C. Human papillomavirus DNA in sera of cervical cancer patients as tumor marker. Cancer Lett., 202: 231-239, 2003.
13. Eads, C. A., Danenberg, K. D., Kawakami, K., Saltz, L. B., Blake, C., Shibata, D., Danenberg, P. V., and Laird, P. W. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res., 28: E32, 2000.
14. Eads, C. A., Lord, R. V., Wickramasinghe, K., Long, T. I., Kurumboor, S. K., Bernstein, L., Peters, J. H., DeMeester, S. R., DeMeester, T. R., Skinner, K. A., and Laird, P. W. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res., 61: 3410-3418, 2001.
15. Wong, Y. F., Cheung, T. H., Lo, K. W. K., Chan, L. K. Y., Heung, M. S., Cheung, A. Y. K., Herman, J. G., and Chung, T. K. H. Multiple gene promoter hypermethylation in tumor and serum of cervical squamous cell carcinoma patients. Proc. Am. Assoc. Cancer Res., 44: 74, 2003.
16. Wong, I. H., Lo, Y. M., and Johnson, P. J. Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring. Ann. N. Y. Acad. Sci., 945: 36-50, 2001.
17. Lee, T. L., Leung, W. K., Chan, M. W., Ng, E. K., Tong, J. H., Lo, K. W., Chung, S. C., Sung, J. J., and To, K. F. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin. Cancer Res., 8: 1761-1766, 2002.
18. Sanchez-Cespedes, M., Esteller, M., Wu, L., Nawroz-Danish, H., Yoo, G. H., Koch, W. M., Jen, J., Herman, J. G., and Sidransky, D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res., 60: 892-895, 2000.
19. Usadel, H., Brabender, J., Danenberg, K. D., Jeronimo, C., Harden, S., Engles, J., Danenberg, P. V., Yang, S., and Sidransky, D. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res., 62: 371-375, 2002.
20. Klein, C. A., Blankenstein, T. J., Schmidt-Kittler, O., Petronio, M., Polzer, B., Stoecklein, N. H., and Riethmuller, G. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet, 360: 683-689, 2002.
21. Kawakami, K., Brabender, J., Lord, R. V., Groshen, S., Greenwald, B. D., Krasna, M. J., Yin, J., Fleisher, A. S., Abraham, J. M., Beer, D. G., Sidransky, D., Huss, H. T., DeMeester, T. R., Eads, C., Laird, P. W., Ilson, D. H., Kelsen, D. P., Harpole, D., Moore, M. B., Danenberg, K. D., Danenberg, P. V., and Meltzer, S. J. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. (Bethesda), 92: 1805-1811, 2000.
22. Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S. B., and Herman, J. G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res., 59: 67-70, 1999.
23. Hibi, K., Taguchi, M., Nakayama, H., Takase, T., Kasai, Y., Ito, K., Akiyama, S., and Nakao, A. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin. Cancer Res., 7: 3135-3138, 2001.
24. Wong, T. S., Chang, H. W., Tang, K. C., Wei, W. I., Kwong, D. L., Sham, J. S., Yuen, A. P., and Kwong, Y. L. High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin. Cancer Res., 8: 433-437, 2002.
25. Wong, I. H., Lo, Y. M., Zhang, J., Liew, C. T., Ng, M. H., Wong, N., Lai, P. B., Lau, W. Y., Hjelm, N. M., and Johnson, P. J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res., 59: 71-73, 1999.
26. Wong, I. H., Johnson, P. J., Lai, P. B., Lau, W. Y., and Lo, Y. M. Tumor-derived epigenetic changes in the plasma and serum of liver cancer patients. Implications for cancer detection and monitoring. Ann. N. Y. Acad. Sci., 906: 102-105, 2000.
27. Rideout, W. M., III, Eversole-Cire, P., Spruck, C. H., III, Hustad, C. M., Coetzee, G. A., Gonzales, F. A., and Jones, P. A. Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol. Cell. Biol., 14: 6143-6152, 1994.
28. Hahnel, R., Harvey, J., and Kay, P. Hypermethylation of the myogenic gene Myf-3 in human breast carcinomas. Anticancer Res., 16: 2111-2115, 1996.
29. Shannon, B., Kay, P., House, A., and Iacopetta, B. Hypermethylation of the MYF-3 gene in colorectal cancers: associations with pathological features and with microsatellite instability. Int. J. Cancer, 84: 109-113, 1999.
30. Taylor, J. M., Kay, P. H., and Spagnolo, D. V. The diagnostic significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders. Leukemia (Baltimore), 15: 583-589, 2001.